Article
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
Viruses - 14 Jul 2022
Cornberg Markus, Stoehr Albrecht, Naumann Uwe, Teuber Gerlinde, Klinker Hartwig, Lutz Thomas, Möller Hjördis, Hidde Dennis, Lohmann Kristina, Simon Karl-Georg
Abstract excerpt
Using data from the German Hepatitis C-Registry (Deutsche Hepatitis C-Register, DHC-R), we report the real-world safety and effectiveness of glecaprevir/pibrentasvir (GLE/PIB) treatment and its impact on patient-reported outcomes (PROs) in underserved populations who are not typically included in clinical trials, yet who will be crucial for achieving hepatitis C virus (HCV) elimination. The DHC-R is an ongoing,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.